Current Headlines

  1. SandboxAQ And iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery For Glioblastoma 7/16/2025

    SandboxAQ and iOncologi today announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults.

  2. Blocking A Little-Known Protein May Offer New Hope For Devastating Lung Disease 7/15/2025

    Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease.

  3. Corcept Submits New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer 7/14/2025

    Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer.

  4. Integrated Biosciences Unveils First-Of-Its-Kind Optogenetic Screening Platform For Drug Discovery 7/14/2025

    Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, today announced the publication of a landmark study in Cell, introducing its first-of-a-kind optogenetic screening platform.

  5. Harnessing Supercomputing Power For Drug Discovery 7/14/2025

    A collaboration between the University of Miami’s Frost Institute for Data Science and Computing and a precision medicine company has proven that using powerful supercomputers can speed early-stage drug research.

  6. Divamics' AI And Molecular Dynamics Platform Powers Breakthroughs In Metabolic Disease Drug Discovery For Partners 7/14/2025

    Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform.

  7. TandemAI And Perpetual Medicines Announce Strategic Merger To Expand Physics And AI-Based Drug Discovery Capabilities 7/10/2025

    TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a computational design-synthesis platform for peptide drug discovery today announced the companies have merged.

  8. U.S. FDA Accepts New Drug Application For Merck's Doravirine/Islatravir, An Investigational, Once-Daily, Oral, Two-Drug Regimen For Treatment Of Adults With Virologically Suppressed HIV-1 Infection 7/10/2025

    Merck, known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy.

  9. Biocytogen Enters Into Antibody Licensing Agreement With BeOne Medicines To Accelerate Innovative Drug Development 7/9/2025

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies.

  10. Connect Biopharma's Exclusive Licensee In China, Simcere Pharmaceutical, Announced Submission Of Its New Drug Application For Rademikibart For The Treatment Of Atopic Dermatitis In China 7/9/2025

    Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical Co., Ltd. (“Simcere”), has submitted its New Drug Application for rademikibart to the National Medical Products Administration of China (“NMPA”) for the treatment of atopic dermatitis (“AD”) in adults and adolescents.